Ex vivo treatment of macrophages from patients with CGD and NOX2-deficient mice with IL-4 or IL-13 leads to re-establishment of normal efferocytosis, as do monocytes treated with the PPARγ agonist, pioglitazone (a drug for treatment of type 2 diabetes) (32, 43). The gene discussed is PPARG; the disease is chronic granulomatous disease.